As a neurologist with more than 30 years in the field of Alzheimer’s disease, I have had many heartbreaking conversations with patients and their loved ones. More than 6 million people in America are living with Alzheimer’s disease, and that staggering number is expected to double within the next 30 years unless there is a change. However, I am more optimistic about that change and physicians’ ability to slow the course of this devastating illness than I have ever been in the past.

The US Food & Drug Administration (FDA) has made 2 updates to the packaging label for an approved treatment for Parkinson disease psychosis.

Clinicians from Switzerland are urging caution when prescribing an anti-amyloid medication in a patient with Alzheimer's disease (AD) also taking a selective serotonin reuptake inhibitor (SSRI) antidepressant.

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies.

With three positive and three negative Phase 3 trials of second-generation anti-amyloid antibodies to draw upon, Alzheimerologists now have more data to mine for what works and what does not. At last month’s Alzheimer’s Association International Conference in Amsterdam, scientists pored over gantenerumab and lecanemab data, hunting for clues of which parameters might predict success. And clues they found.

93% of patients in study had an antibody response against beta-amyloid

Patients starting SSRIs and lecanemab may warrant close monitoring

UB-311 could offer multiple competitive advantages over licensed passive immunotherapies, including less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of ARIA-E

The drugs clear sticky plaques from the brain. But they are not for everyone, experts caution

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug meeting with the Food and Drug Administration related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). The CAB includes six members with diverse backgrounds and expertise in dementia, Alzheimer’s disease, inflammation, neurodegenerative disorders, and drug development.

In the first decade of the last century a young German psychiatrist discovered a new disease. But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis. As a result the “A-word” now has a particularly scary connotation for senior citizens. Perhaps it is because it is normal to experience memory loss as we age.

In the first decade of the last century, a young German psychiatrist discovered a new disease. But it took the worldwide medical community some seven decades to fully acknowledge the devastating impact of Dr. Alois Alzheimer’s diagnosis. As a result, the “A-word” now has a particularly scary connotation for senior citizens. Perhaps it is because it is normal to experience memory loss as we age.